Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: Clinical implications of recent studies

Current Opinion in Infectious Diseases

Volumn 21, Issue 4, 2008, Pages 409-414

  Marr, Kieren A ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Division of Pediatric Infectious Diseases   (United States)

Author keywords

Invasive fungal infections; Prophylaxis; Transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

CANDIDA; CHEMOPROPHYLAXIS; CREATININE BLOOD LEVEL; DRUG CHOICE; DRUG INDICATION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; DRUG EFFECT; FUNGUS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CHEMOPREVENTION; FUNGI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES;

EID: 49049100517     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328307c7d9     Document Type: Review

References (48)

1. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552.
2. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
3. Marr K, Seidel K, Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-2061.
4. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138:705-713.
5. Karthaus M, Cornely OA, Ullmann AJ. Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med 2004; 140:579-580; author reply 581-582.
6. Mossad SB. Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med 2004; 140:580-581; author reply 581-582.
7. Powers JH, Higgins KM. Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med 2004; 140:580; author reply 581-582.
8. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527-1533.
9. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557-1559.
10. Upton A, McCune JS, Kirby KA, et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13:760-764.
11. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:1487-1498.
12. Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 2007; 86:324-333.
13. Mezger M, Steffens M, Beyer M, et al. Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood 2008; 111:534-536. This study, although small for one of its type, is thoughtfully designed and a good example of the types of genetic associations studies that will be increasingly published in the future. Results of this one are particularly compelling because in-vitro assays are performed that support a phenotypic impact of the polymorphism.
14. Mezger M, Steffens M, Semmler C, et al. Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clin Microbiol Infect 2008; 14:228-234.
15. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-1416.
16. Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644-1650.
17. Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30:551-554.
18. Pasquale T, Tomada JR, Ghannoun M, et al. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 2008; 61:219.
19. Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51:1876-1878.
20. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007; 59:1076-1083.
21. Garcia-Effron G, Katiyar SK, Park S, et al. A naturally-occurring Fks1p proline to alanine amino acid cChange in Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 28 Apr [Epub ahead of print].
22. Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hemato-logic diseases. Biol Blood Marrow Transplant 2007; 13:771-777.
23. Hara S, Yokote T, Oka S, et al. Endophthalmitis due to Trichosporon beigelii in acute leukemia. Int J Hematol 2007; 85:415-417.
24. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42:753-757.
25. Roman E, Osunkwo I, Militano O, et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50:325-330.
26. Jansen J, Akard LP, Wack MF, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 2006; 49:397-404.
27. Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135-141.
28. El-Cheikh J, Faucher C, Furst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:301-306.
29. Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12:235-240.
30. Mohammad RA, Klein KC. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother 2006; 40:2148-2154.
31. Griese M, Schams A, Lohmeier KP. Amphotericin B and pulmonary surfactant. Eur J Med Res 1998; 3:383-386.
32. Alexander BD, Dodds Ashley ES, Addison RM, et al. Noncomparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8:13-20.
33. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-1408. The study has shortcomings, in that it was prematurely discontinued due to slow accrual. Perhaps more importantly, little data are presented to evaluate detailed measures of pulmonary safety. However, it is one of only two randomized trials performed to evaluate the efficacy of aerosolized amphotericin B products, and results appear suggestive of efficacy.
34. Ullmann A, Lipton J, Vesole D, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347. This is a large, well designed trial that led to approval of posaconazole for use as prophylaxis in this setting.
35. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359. Another large, well designed trial that led to approval of posaconazole for use as prophylaxis in neutropenic patients. Results of this study are particularly compelling, as there was a trend to better survival among patients who received posaconazole.
36. ••]; as such, it should be read with the primary results of the trial.
37. Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41 (Suppl 6):S381-S386.
38. Wingard J, Carter S, Walsh T, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow (BMT) patients. In: 49th American Society of Hematology Annual Meeting; Atlanta, GA; 2007.
39. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55:209-212.
40. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-456. Results demonstrate the variability in voriconazole levels observed with currently recommended dosing, and how this may have an impact on breakthrough infection.
41. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-1535.
42. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-587.
43. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39:425-429.
44. Kontoyiannis D, Wessel V, Bodey G, Rolston K. Zygomycosis in the 1990s in a tertiary care center. Clin Infect Dis 2000; 30:851-856.
45. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-952.
46. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-746.
47. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552-559.
48. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-1769.